• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Orphan drug designation for pracinostat, volasertib and alvocidib in AML.

作者信息

Bose Prithviraj, Grant Steven

机构信息

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA.

出版信息

Leuk Res. 2014 Aug;38(8):862-5. doi: 10.1016/j.leukres.2014.06.007. Epub 2014 Jun 17.

DOI:10.1016/j.leukres.2014.06.007
PMID:24996975
Abstract
摘要

相似文献

1
Orphan drug designation for pracinostat, volasertib and alvocidib in AML.普拉西诺司他、沃拉塞替布和阿沃西地布在急性髓系白血病中的孤儿药认定。
Leuk Res. 2014 Aug;38(8):862-5. doi: 10.1016/j.leukres.2014.06.007. Epub 2014 Jun 17.
2
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.阿沃西地布（黄酮哌啶醇）在急性髓系白血病中的临床活性。
Leuk Res. 2015 Dec;39(12):1312-8. doi: 10.1016/j.leukres.2015.10.010. Epub 2015 Oct 19.
3
Emergence of crenolanib for FLT3-mutant AML.克立替尼在 FLT3 突变型 AML 中的应用。
Blood. 2013 Nov 21;122(22):3547-8. doi: 10.1182/blood-2013-10-528992.
4
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.阿沃西地布（黄酮哌啶醇）用于治疗慢性淋巴细胞白血病。
Expert Opin Investig Drugs. 2016 Jun;25(6):729-34. doi: 10.1517/13543784.2016.1169273. Epub 2016 Apr 7.
5
Novel drugs for older patients with acute myeloid leukemia.新型药物治疗老年急性髓系白血病患者。
Leukemia. 2015 Apr;29(4):760-9. doi: 10.1038/leu.2014.244. Epub 2014 Aug 21.
6
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.蛋白酶体抑制增强了沃拉塞替布在体外诱导急性髓系白血病细胞有丝分裂停滞的效果，并在体内延长了生存期。
Oncotarget. 2017 Mar 28;8(13):21153-21166. doi: 10.18632/oncotarget.15503.
7
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.普拉西诺司他联合阿扎胞苷治疗新诊断的老年急性髓系白血病：一项 2 期研究结果。
Blood Adv. 2019 Feb 26;3(4):508-518. doi: 10.1182/bloodadvances.2018027409.
8
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.波洛样激酶强效选择性抑制剂沃拉泽替布在急性髓系白血病临床前模型中的疗效及作用机制
J Pharmacol Exp Ther. 2015 Mar;352(3):579-89. doi: 10.1124/jpet.114.221150. Epub 2015 Jan 9.
9
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.克立替尼对耐药性 FLT3-ITD 阳性急性髓细胞性白血病模型具有活性。
Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.
10
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.研究性成纤维细胞生长因子样酪氨酸激酶 3 抑制剂治疗急性髓系白血病。
Expert Opin Investig Drugs. 2014 Jul;23(7):943-54. doi: 10.1517/13543784.2014.911839. Epub 2014 Apr 21.

引用本文的文献

1
Total Synthesis of Rohitukine and Dysoline and Their Anticancer Analogues Flavopiridol and IIIM-290.洛希图碱和地索林及其抗癌类似物黄酮哌啶醇和IIIM-290的全合成。
ACS Omega. 2025 Aug 16;10(33):38240-38254. doi: 10.1021/acsomega.5c06387. eCollection 2025 Aug 26.
2
Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy.使用联合虚拟筛选策略发现一种具有高抑制活性的新型PLK1抑制剂。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2467798. doi: 10.1080/14756366.2025.2467798. Epub 2025 Mar 7.
3
Detection of Genomic Structural Variations Associated with Drug Sensitivity and Resistance in Acute Leukemia.
急性白血病中与药物敏感性和耐药性相关的基因组结构变异的检测
Cancers (Basel). 2024 Jan 18;16(2):418. doi: 10.3390/cancers16020418.
4
Targeting CDK1 in cancer: mechanisms and implications.靶向癌症中的细胞周期蛋白依赖性激酶1：机制与意义
NPJ Precis Oncol. 2023 Jun 13;7(1):58. doi: 10.1038/s41698-023-00407-7.
5
Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.开发并验证一种快速 LC-MS/MS 法用于定量测定阿伐卡必：人肝微粒体中的体外和体内代谢稳定性预测。
Molecules. 2023 Mar 4;28(5):2368. doi: 10.3390/molecules28052368.
6
Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia.转铁蛋白引导的智能纳米囊泡增强临床PLK1抑制剂对急性髓系白血病的靶向性和效力。
Bioact Mater. 2022 Sep 20;21:499-510. doi: 10.1016/j.bioactmat.2022.08.032. eCollection 2023 Mar.
7
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.贝利司他（PXD-101）与硼替佐米（万珂，PS-341）用于复发或难治性急性白血病和骨髓增生异常综合征患者的1期研究。
Leuk Lymphoma. 2021 May;62(5):1187-1194. doi: 10.1080/10428194.2020.1861270. Epub 2020 Dec 28.
8
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.BI6727，一种有前景的 Polo 样激酶 1 抑制剂，对 Burkitt 淋巴瘤细胞有效。
J Int Med Res. 2020 May;48(5):300060520926093. doi: 10.1177/0300060520926093.
9
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.急性髓系白血病中通过细胞周期蛋白依赖性激酶抑制作用实现MCL-1的转录沉默
Front Oncol. 2019 Dec 12;9:1205. doi: 10.3389/fonc.2019.01205. eCollection 2019.
10
Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy.急性髓系白血病中髓系细胞白血病-1的依赖性：一种患者治疗的新方法。
Oncotarget. 2019 Feb 8;10(12):1250-1265. doi: 10.18632/oncotarget.26579.